Eli Lilly’s (NYSE:LLY) Trulicity’s (dulaglutide) Phase III cardiovascular outcome trial (CVOT) excited expert debate on whether its similar long-acting formulation to Novo Nordisk’s (CPH:NOVO-B) Victoza (liraglutide) should encourage superior CV protection outcomes.
Whilst some argued this could be the case, noting both are GLP-1 receptor agonists, others said Victoza’s superior CV protection success may be associated with its weight-loss effects, which are unclear for Trulicity.
Although all agreed CV harm will unlikely be shown, some noted Trulicity’s once-weekly formulation may cause different CV outcomes to the previous once-daily agents, potentially inducing neither CV harm nor protection like Sanofi’s (EPA:SAN) Lyxumia (lixisenatide).
Its infrequent administration may ease gastrointestinal (GI) toxicities common to the drug class, some added, whilst CV protection superiority over Victoza would encourage Truclity’s uptake. Trulicity’s easy-to-administer formulation may also benefit certain patient subgroups.